Corporate Social Responsibility Header.jpg

Corporate Social Responsibility

Corporate Social Responsibility

An introduction to BBI Solutions Corporate Social Responsibilty from our CEO, Dr. Mario Gualano:

At BBI our values and principles are deeply rooted in our daily work. We strive to deliver exceptional products and technologies that our customers, and ultimately their patients, rely on. Through innovation, partnership, effective delivery and the collaboration of our people, we help to set industry standards, engender trust and build our reputation for excellence.

Founded upon the success of the superior quality and performance of our gold reagents, our organisation has grown to include six operating facilities worldwide that work together to globally serve the science of diagnostics for better healthcare outcomes and clinical decision making. Through innovation, partnership, effective delivery and the collaboration of our people, we constantly strive to help set industry standards, engender trust and build our reputation for excellence.

We are a determined and dynamic company with expert, passionate and energetic employees who all work hard to ensure quality, value and superior service for our customers. We have a focus on employee safety and ensuring we bring fairness across all our facilities.

During our financial year 2020, we have further increased our focus on corporate social responsibility. At BBI we strive to be more environmentally responsible. We have taken many steps as a company to achieve this, from updating our global waste management processes, introducing electrical charging points for vehicles at our HQ and reducing our facility footprint through specific UK site consolidation.

Over the last 2 years we have emphasised our focus on Continuous Improvements efforts across all sites which many of our colleagues have engaged in and driven forward with these improvements which have in turn led to a number of environmental and energy savings. In the coming years we will continue and build on the good work that has already taken place in 2020. At the end of this report you will be able to see the opportunities we will be focusing on over the next 3-5 years


 

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox